News
NextCure's NC605 Shows Promise in Bone Disease Treatment
July 24, 2025 • News
Companies mentioned:
NextCure, Inc. shares are trading higher after presenting preclinical data indicating that its novel anti-Siglec-15 antibody, NC605, improves bone microarchitecture and reduces fracture incidence in a model of osteogenesis imperfecta.